Alzheimer's disease (AD) is currently being addressed by intensive investment in pre-clinical and clinical research on the amyloid hypothesis, but concern remains about the validity of the concept that soluble Aβ oligomers are principally responsible for initiating AD phenotypes. Here, we apply well-defined Aβ oligomers isolated from AD brains or made synthetically to document a systematic accrual of first subtle and then more profound changes in certain synaptic proteins in both primary neuronal cultures and behaving adult mice. Among the first (within hours) synaptic changes are selective decreases in surface levels of certain (e.g., GluA1) but not other (e.g., GluN2B) glutamate receptors and subtle microglial activation. After 4 days, numerous additional synaptic proteins are altered. Moreover, Aβ oligomers induce hyperphosphorylation of tau and subsequent neuritic dystrophy. All changes are prevented by scyllo-inositol in a dose-and stereoisomer-specific manner. Mechanistically, scyllo-inositol interferes quantitatively with the binding of Aβ oligomers to plasma membranes. These comprehensive analyses in culture and in vivo provide direct evidence that diffusible oligomers of human Aβ (without plaques) induce multiple phenotypic changes in healthy neurons, indicating their role as principal endogenous cytotoxins in AD. Our data recommend a re-examination of scyllo-inositol as an anti-oligomer therapeutic in humans with early AD.
Introduction
Despite almost two decades of research on the apparent neurotoxicity of various assembly states of amyloid β-protein (Aβ), concerns about the hypothesis that soluble oligomeric forms are the principal initiating neurotoxins in Alzheimer's disease (AD) remain prevalent (Benilova et al., 2012; Herrup, 2010; Pimplikar et al., 2010; Robakis, 2011; Small and Duff, 2008) . The mechanistic uncertainty about whether soluble Aβ oligomers in the human brain are responsible for early and progressive synaptotoxicity has been augmented by the prominent failures of several experimental anti-Aβ therapeutics to achieve their prespecified cognitive and behavioral endpoints in Phase 3 human trials. Nevertheless, a very large preclinical and clinical effort to validate anti-amyloid agents continues and represents by far the largest sector of AD therapeutic development at this writing. Accordingly, it becomes even more important to attempt to rigorously confirm or deny the effects of well-defined, diffusible Aβ species on neurons, particularly their synapses, and on innate immune cells in the brain.
Here, we have coupled extensive primary neuronal culture analyses of both synthetic and natural (AD brain-derived) soluble Aβ oligomers with the much less commonly used in vivo paradigm of intracerebroventricular (ICV) microinjection of oligomers into behaving, wild-type adult mice, in order to examine the temporal evolution of the acute and subacute cellular effects. We have coupled these in vitro and in vivo analyses of oligomer bioactivity with the controlled application of an anti-Aβ small-molecule therapy, scyllo-inositol, in comparison to its stereoisomer, chiro-inositol, which has the same empirical formula but is far less active. We report a diverse array of time-dependent biological effects, including tau hyperphosphorylation and neuritic dystrophy, of soluble oligomers applied at pathophysiologically relevant concentrations. Then, we examine the mechanism of the highly consistent protection that scyllo-inositol provides, both in neuronal culture and in vivo. Our results directly support the Aβ oligomer hypothesis for the initiation of progressive neural injury and also provide a rationale for continuing the clinical development of scyllo-inositol, particularly in light of statistically significant benefits on certain cognitive and biomarker endpoints observed in mild AD patients during a 'failed' Phase 2 clinical trial of this natural product (Salloway et al., 2011) .
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Abbreviations: Aβ, amyloid β-protein; AD, Alzheimer's disease; IP, immunoprecipitation; SEC, size exclusion chromatography; AβM, Aβ monomers; AβD, LDS-stable Aβ dimers; Chiro, chiro-inositol; Scyllo, scyllo-inositol; ICC, immunocytochemistry; IHC, immunohistochemistry; WB, Western blotting; PSD95, postsynaptic density protein 95; GluN1/2A/2B, NMDA-type glutamate receptor 1/2A/2B; GluA1, AMPAtype glutamate receptor 1; SYP, synaptophysin; SYN-1, synapsin-1; VGLUT2, vesicular glutamate transporter 2; wt, wild-type; ICV, intracerebroventricular; dpi, day post-injection; DG, dentate gyrus of hippocampus; CA3, Cornu Ammonis area 3 of hippocampus; SPM, synaptic plasma membrane; PSD, post-synaptic density.
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